Focus: OH Pharmaceutical is a generic drug manufacturer headquartered in Crown Point, Indiana, with a narrow portfolio focused on oncology and hematology treatments. The company operates as a generics player with heavy concentration in a single asset.
Profile data last refreshed 2d ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow OH Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's only revenue driver, generating 100% of corporate revenue but with minimal Part D spending, indicating mature/declining market.
Help build intelligence for OH Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from OH Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE competitor to Azacitidine but no Part D spending data suggests minimal commercial traction.
Post-LOE generic with no reported Part D spending; likely niche or declining revenue contributor.
Proteasome inhibitor post-LOE with no Part D data; portfolio filler with unclear commercial value.
Niche orphan/rare disease indication; likely minimal revenue but lower competition than commoditized oncology agents.
3 discontinued, 6 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSupply chain volatility with multiple Azacitidine availability conflicts suggests operational execution risk and potential job instability if manufacturing issues worsen.